Here's Why You Should Retain Catalent (CTLT) Stock for Now
https://www.zacks.com/stock/news/2198761/here-s-why-you-should-retain-catalent-ctlt-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198761
Dec 15, 2023 - Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
0
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
https://www.zacks.com/stock/news/2198721/align-s-algn-new-launches-aid-macroeconomic-woes-linger?cid=CS-ZC-FT-analyst_blog|zer_report_update-2198721
Dec 15, 2023 - Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
0
Here's Why You Should Buy Neogen (NEOG) Stock Now
https://www.zacks.com/stock/news/2198536/here-s-why-you-should-buy-neogen-neog-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198536
Dec 15, 2023 - Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.
0
Integra (IART) to Advance ENT Division With New Buyout Deal
https://www.zacks.com/stock/news/2198095/integra-iart-to-advance-ent-division-with-new-buyout-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198095
Dec 14, 2023 - Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
0
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
https://www.zacks.com/stock/news/2197835/myriad-genetics-mygn-new-partnerships-aid-amid-fx-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2197835
Dec 14, 2023 - Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
0
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
https://www.zacks.com/stock/news/2197789/here-s-why-you-should-retain-glaukos-gkos-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197789
Dec 14, 2023 - Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
0
Medtronic (MDT) Expands AI-Driven Care With New Partnership
https://www.zacks.com/stock/news/2197563/medtronic-mdt-expands-ai-driven-care-with-new-partnership?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197563
Dec 13, 2023 - Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.
0
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
https://www.zacks.com/stock/news/2197564/here-s-why-you-should-retain-exact-sciences-exas-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197564
Dec 13, 2023 - Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
0
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
https://www.zacks.com/stock/news/2197534/qiagen-s-qgen-strategic-alliances-aid-amid-macro-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2197534
Dec 13, 2023 - QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
0
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
https://www.zacks.com/stock/news/2197283/integer-holdings-corporation-itgr-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2197283
Dec 13, 2023 - Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0